Group 1 - The company emphasizes a long-term development philosophy and continuously formulates strategic development plans [1] - The company is focused on deepening core business, market expansion, and capability upgrades [1] - Major operational information should be disclosed in accordance with legal information disclosure requirements [1]

Core Viewpoint - The article discusses the environmental protection tax and various scenarios in which companies can benefit from tax reductions or exemptions based on their pollution emissions and compliance with environmental standards [2][3]. Group 1: Tax Benefits for Different Industries - Chemical companies can reduce their environmental protection tax by 75% if their emissions are below 30% of the national standards, and by 50% if below 50% [2]. - Agricultural production, excluding large-scale breeding, is exempt from the environmental protection tax [3]. - Transportation companies with vehicles that emit pollutants are subject to the environmental protection tax unless they meet specific exemptions [3]. - Companies that utilize solid waste like smelting slag and fly ash in compliance with environmental standards can be exempt from the environmental protection tax [3]. - Food processing plants that discharge wastewater into municipal treatment facilities are not required to pay the environmental protection tax [3]. Group 2: Policy References - The article references the "Environmental Protection Tax Law of the People's Republic of China" and its implementation regulations as the basis for the discussed tax benefits [3].

盘前要闻 1、八部门：到2027年中国人工智能关键核心技术实现安全可靠供给 类型：行业 情绪影响：正面 工信部等八部门印发《"人工智能+制造"专项行动实施意见》，意见指出，到2027年，我国人工智能关 键核心技术实现安全可靠供给。意见还指出，推动智能芯片软硬协同发展，支持突破高端训练芯片、人 工智能服务器、智算云操作系统等关键核心技术。 2、锂电"反内卷"力度升级：多部门联合召开动力储能电池行业座谈会 类型：行业 情绪影响：正面 1月7日，多部门联合召开动力和储能电池行业座谈会，研究部署规范产业竞争秩序相关工作。有知情人 士透露，参会企业包括国内Top10的动力电池企业、几家头部储能电池企业和集成商等，共计10余家。 有参会人士透露，此次会议总体围绕行业"反内卷"工作，包括要求企业实现控产能、管价格战、保护专 利等内容。 3、央行今日开展1.1万亿买断式逆回购操作，专家称月内将继续注入流动性 类型：宏观 情绪影响：正面 机构观点 央行1月8日将开展11000亿元买断式逆回购操作，期限为3个月。考虑到今日有11000亿买断式逆回购到 期，本次操作为等量续作。专家预计央行将于1月15日左右开展6个月期买断式逆回购 ...

Industry Updates - The National Drug Administration held a meeting emphasizing key tasks for 2026, including ensuring high-level drug safety, supporting the pharmaceutical industry's quality improvement, enhancing legal standards in drug regulation, and advancing modernization in drug supervision [4] - The State Administration for Market Regulation and the National Internet Information Office jointly released regulations to prevent unreasonable restrictions on platform operators and protect consumer rights in online transactions [4] - The Ministry of Industry and Information Technology announced the implementation of "Artificial Intelligence + Manufacturing" initiatives, focusing on accelerating the application of humanoid robots and enhancing the industrialization of AI terminals [7] Company News - Bestme's subsidiary, Yong'an Chemical, is facing criminal charges for environmental pollution due to interference with automatic monitoring facilities [13] - Heng Rui Medicine's subsidiary received approval for a new innovative drug, which is the first of its kind to be approved for treating specific types of cancer [14] - Guangqi Technology signed contracts worth 2.15 billion yuan for the mass production of metamaterials, indicating strong demand in the market [14] - Zhongke Blue Communication expects a significant profit increase of 366.51% to 376.51% in 2025, driven by investments in other companies [15] - Chuanjinno anticipates a net profit of 430 million to 480 million yuan in 2025, reflecting a growth of 144.24% to 172.64% [16] Market Trends - Analysts predict a substantial increase in Samsung Electronics' Q4 2025 earnings, with a projected 160% year-on-year profit surge due to a severe chip shortage driving up storage chip prices [10] - The postal industry plans to introduce policies to promote the application of unmanned delivery technologies, which could lead to significant growth in logistics efficiency [11] - Institutions are increasingly focusing on the semiconductor sector, with a notable recovery in the storage segment, indicating a healthier supply-demand structure [18][19]

Market Overview - The three major A-share indices experienced a slight increase on January 7, with total trading volume in the Shanghai and Shenzhen markets reaching 2.88 trillion yuan, an increase of over 49 billion yuan compared to the previous day [1] - More than 2,100 stocks closed higher, with notable gains in sectors such as storage chips, state-owned capital holdings, and advanced packaging [1] Historical Highs - A total of 99 stocks reached their historical closing highs, excluding newly listed stocks from the past year. The electronics, machinery equipment, and non-ferrous metals sectors had the highest concentration of stocks hitting new highs, with 27, 13, and 11 stocks respectively [1] - The average increase for stocks that reached historical highs was 7.25%, with stocks like Shaoyang Hydraulic, Meihua Medical, and Nanda Optoelectronics hitting the daily limit [1] Top Gainers - The top gainers among stocks that reached historical highs included: - Shaoyang Hydraulic (41.33 yuan, +20.01%) - Meihua Medical (41.56 yuan, +20.01%) - Andar Intelligent (170.08 yuan, +20.00%) - Nanda Optoelectronics (55.19 yuan, +20.00%) [2] Institutional Activity - In the market, 17 stocks were net bought by institutions, with five stocks seeing net purchases exceeding 1 billion yuan. Notably, Sanbo Brain Science and Shunhao Co. received over 2 billion yuan in net purchases [2] - Conversely, Jin Feng Technology faced the highest net sell-off by institutions, amounting to over 400 million yuan, followed by Meihua Medical and Chip Source Micro with net sells of 371 million yuan and 241 million yuan respectively [3] Northbound Capital Flow - Northbound funds saw net purchases in 14 stocks, with Nanda Optoelectronics, Sanbo Brain Science, and Lei Ke Defense leading with amounts exceeding 1 billion yuan [4] - On the sell side, Jin Feng Technology topped the list with a net sell amount of 92.58 million yuan, followed by Yunhan Chip City and Shunhao Co. with net sells exceeding 40 million yuan [5] Company Announcements - Zhongke Lanyun (688332) projected a net profit increase of 366.51% to 376.51% for 2025, driven by significant growth in the fair value of investments in Moer Thread and Muxi Co. [7] - Su Meida plans to acquire a 16.92% stake in Blue Science High-Tech to achieve control [7] - Baomo Co. is planning a change in control by its actual controller [7] - Puli Te's LCP film products are suitable for use as flexible electrode materials in brain-computer interfaces [7] - Chuanjin Nuo expects a net profit increase of 144.24% to 172.64% for 2025 [7]

Core Viewpoint - The article highlights the significant profit growth of several A-share listed companies in their 2025 performance forecasts, indicating a positive trend across various industries, including military, pharmaceuticals, and technology [3][4]. Group 1: Company Performance - Northern Navigation expects a net profit of CNY 110 million to CNY 140 million for 2025, representing a year-on-year increase of 86.32% to 137.14% from CNY 59.04 million [5]. - The company reported a non-recurring net profit of CNY 89 million to CNY 119 million, with a year-on-year growth of 121.10% to 195.63% [5]. - Northern Navigation's revenue for the first three quarters of 2025 reached CNY 2.468 billion, with a net profit of CNY 125 million, laying a solid foundation for annual performance growth [5]. Group 2: Industry Trends - Multiple A-share companies have disclosed profit growth forecasts, with Zhongtai Co. leading with a median year-on-year increase of 677.22% [6]. - Other companies like Chuanhua Zhili and Bai'ao Saitu expect median year-on-year increases of 308.82% and 303.57%, respectively [6]. - The performance growth is primarily concentrated in sectors such as machinery, public utilities, and steel, driven by steady industry demand and internal improvements in product structure and operational efficiency [7]. Group 3: Market Reactions - Northern Navigation's stock price has seen significant increases, with a cumulative rise of over 45% since mid-December 2025, reflecting positive market sentiment [5]. - The company issued a clarification regarding its involvement in the commercial aerospace sector, stating it has no related business or orders, despite market speculation [6]. Group 4: Growth Drivers - Different industries exhibit unique growth drivers; for instance, Ding Tai High-Tech benefits from surging demand for servers and data centers, while Zhongcai Technology sees growth from optimized product structures and increased sales of wind turbine blades [7]. - Companies like Whirlpool and Huayou Cobalt have also reported profit growth due to increased orders and advantages from industrial integration [7].

Core Viewpoint - The A-share listed companies are showing significant profit growth in their 2025 performance forecasts, with notable contributions from sectors such as military, pharmaceuticals, and commercial aerospace [1][3]. Group 1: Company Performance - Northern Navigation expects a net profit of CNY 110 million to CNY 140 million for 2025, representing a year-on-year increase of 86.32% to 137.14% from CNY 59.0374 million [1]. - The non-recurring net profit for Northern Navigation is projected to be CNY 89 million to CNY 119 million, with a year-on-year growth of 121.10% to 195.63% [1]. - Kangchen Pharmaceutical anticipates a net profit of CNY 145 million to CNY 175 million for 2025, a substantial increase of 243% to 315% from CNY 42.22 million [2][3]. - The non-recurring net profit for Kangchen Pharmaceutical is expected to rise by 350% to 447%, reaching CNY 140 million to CNY 170 million [2]. Group 2: Industry Trends - The commercial aerospace sector has been active, with Northern Navigation's stock price increasing over 45% since mid-December 2025 [1]. - Other companies, such as Zhongtai Co., expect a median year-on-year net profit increase of 677.22%, leading among disclosed forecasts [3]. - Industries such as machinery, public utilities, and steel are seeing significant profit growth, driven by steady demand expansion and internal improvements in product structure and operational efficiency [3].

★ 宏观动态 ★ 央行：明日开展11000亿元买断式逆回购操作 央行公告，为保持银行体系流动性充裕，2026年1月8日，中国人民银行将以固定数量、利率招标、多重价位中 标方式开展11000亿元买断式逆回购操作，期限为3个月（90天）。 国家外汇局：截至2025年12月末我国外汇储备规模为33579亿美元 国家外汇管理局统计数据显示，截至2025年12月末，我国外汇储备规模为33579亿美元，较11月末上升115亿美 元，升幅为0.34%。 2025年12月，受主要经济体货币政策、宏观经济数据等因素影响，美元指数下跌，全球金 融资产价格涨跌互现。汇率折算和资产价格变化等因素综合作用，当月外汇储备规模上升。我国不断巩固拓展 经济稳中向好势头，经济长期向好的支撑条件和基本趋势没有改变，有利于外汇储备规模保持基本稳定。 工信部：到2028年推动不少于5万家企业实施新型工业网络改造升级 工信部印发《工业互联网和人工智能融合赋能行动方案》。目标到2028年，工业互联网与人工智能融合赋能水 平显著提升。满足人工智能工业应用高通量、低时延、高可靠、低抖动通信需求的新型工业网络规模持续扩 大，在原材料、装备制造、消费品、电子信 ...

Investment Rating - The report indicates that the overall credit risk of the pharmaceutical manufacturing industry is controllable, with stable operating performance expected in 2026 [5][6][11]. Core Insights - The pharmaceutical manufacturing industry has shown a slight increase in the number of enterprises, with a deepening degree of differentiation within the industry. Revenue and total profit have remained stable year-on-year due to a stabilizing policy environment [6][11]. - The "14th Five-Year Plan" supports the development of innovative drugs, with the scale of license-out exceeding the total for 2024 in the first three quarters of 2025, indicating a positive outlook for innovative drug development [6][11]. - The industry has maintained net inflows in bond market financing, with overall debt pressure being manageable despite a significant amount of bonds maturing within one year [6][11]. Industry Fundamentals Industry Policy - The pharmaceutical industry is highly sensitive to policy changes, with a "three medical linkage" policy framework encouraging innovation, improving medical services, and optimizing medical insurance payments. The "14th Five-Year Plan" emphasizes the strategic importance of the biomanufacturing industry [7][8]. - Recent policies have focused on cost control in medical insurance, reforming payment methods, and promoting the development of generic drugs and innovative medicines [7][8]. Industry Operating Conditions - As of the end of 2024, the number of pharmaceutical manufacturing enterprises in China reached 9,793, with a slight increase in the number of loss-making enterprises, indicating a growing differentiation within the industry [12][11]. - The basic medical insurance fund's income and expenditure structure has improved, with significant cost control effects observed [11][12]. Financial Performance Growth Metrics - In 2024, the pharmaceutical manufacturing industry reported total revenue of 25,298.5 billion yuan and total profit of 3,420.7 billion yuan, with minor fluctuations expected in 2025 [22][23]. - For the first three quarters of 2025, total revenue was 18,211.4 billion yuan, a decrease of 2.00% year-on-year, while total profit was 2,534.8 billion yuan, down 0.70% [22][23]. Profitability - The gross profit margin for the pharmaceutical manufacturing industry has shown a declining trend, with the sales expense ratio remaining stable and the management expense ratio slightly decreasing [24][25]. - The net cash flow from operating activities has been declining, indicating potential liquidity risks [24][25]. Leverage and Solvency - The leverage level in the pharmaceutical manufacturing industry remains low, with a slight fluctuation observed in recent years. The debt-to-asset ratio has been stable, and the overall solvency indicators are at a high level [30][31]. - As of September 2025, the liquidity ratios have slightly improved, indicating a manageable debt repayment risk [31][32]. Bond Market Performance Issuance Overview - In 2025, the pharmaceutical manufacturing industry experienced a net inflow in bond market financing, with a total of 104 bonds issued amounting to 713.80 billion yuan [39][41]. - The industry has seen a concentration of bond issuers at the AA+ level, with a significant number of private enterprises involved [39][41].

Market Overview - The Hong Kong stock market experienced a downward trend, with the Hang Seng Index closing down 0.94% at 26,458.95 points and a total turnover of HKD 2,761.34 million [1] - The Hang Seng China Enterprises Index fell by 1.14% to 9,138.75 points, while the Hang Seng Tech Index decreased by 1.49% to 5,738.52 points [1] - Zheshang International noted that the fundamentals of the Hong Kong market remain weak, with a decline in the funding environment, while Goldman Sachs maintains an "overweight" rating on Chinese A-shares and H-shares, citing attractive risk-reward ratios [1] Blue Chip Performance - WuXi Biologics (02269) led blue-chip stocks, rising 5.92% to HKD 36.12, contributing 11.87 points to the Hang Seng Index [2] - Other notable blue-chip performers included Innovent Biologics (01801) up 5.38% and WuXi AppTec (02359) up 4.91%, while Alibaba (09988) fell 3.25%, dragging the index down by 65.17 points [2] Sector Highlights Pharmaceutical Sector - The pharmaceutical sector continued its upward trend, with notable gains from Rongchang Biologics (09995) up 12.93% and Tigermed (03347) up 8.88% [3] - The National Medical Products Administration reported that 76 innovative drugs are expected to be approved by 2025, significantly surpassing the 48 approved in 2024, with a total transaction value exceeding USD 130 billion [4] Nickel Sector - Nickel stocks showed strong performance, with Xinjiang Xinxin Mining (03833) rising 12.28% and Zhongwei New Materials (02579) up 10% [4] - Nickel prices surged over 20% in the past two weeks, driven by supply constraints from Indonesia, which plans to reduce nickel mining quotas by 2026 [4] Paper Sector - Paper stocks saw significant gains, with Nine Dragons Paper (02689) up 8.97% and Lee & Man Paper (02314) up 6.92% [5] - Several paper companies announced price increases, indicating a reduction in production pressure and a more favorable market environment [5] Coal Sector - Coal stocks generally rose, with Shougang Resources (00639) up 5.98% and China Qinfa (00866) up 5.92% [6] - The Dalian Commodity Exchange saw a surge in coal futures, and analysts expect improvements in supply-demand dynamics for the coal industry [6] Optical Communication Sector - Optical communication stocks rebounded, with Yangtze Optical Fibre (06869) rising 6.75% [6] - The sector was buoyed by strong performances in the U.S. market, particularly from Lumentum and Coherent [7] Notable Stocks - Yadea Group (01585) announced a profit increase, leading to a 4.63% rise in its stock price [8] - Jinli Permanent Magnet (300748) was active, rising 3.65% amid news of potential export restrictions on rare earth materials to Japan [9] - Jitu Express (01519) reached a new high, with a 3.39% increase, reporting significant growth in package volume [10] - GF Securities (01776) faced pressure, dropping 4.09% after announcing a share placement and convertible bond issuance to raise funds for international business development [11]